BioNTech Shares Surged Today
**BioNTech Secures New U.S. Supply Agreement for Comirnaty Vaccine**
BioNTech, the German pharmaceutical company, has announced a new supply agreement with the U.S. government for 105 million doses of its Comirnaty COVID-19 vaccine. This deal comes with an option for an additional 195 million doses, potentially indicating a demand for up to 200 million more doses of Comirnaty.
The new agreement, signed on Wednesday evening, is a clear indication that BioNTech's only commercialized product, the Comirnaty jab, remains in high demand. The U.S. government's decision to secure additional doses could potentially spark similar agreements from other nations.
Shares of BioNTech have climbed by more than 5.6% as of 12:07 p.m. ET on Thursday due to the news of the new supply agreement. The deal, which includes the option to purchase an additional 195 million doses if needed, will see BioNTech and its collaborator, Pfizer, paid $3.2 billion when the government receives the doses it ordered.
However, it's important to note that BioNTech has not recently signed new, publicly announced supply agreements for its Comirnaty vaccine with other countries beyond its existing partnerships. The UK government has confirmed that the Pfizer-BioNTech mRNA (Comirnaty) vaccine will be supplied for the autumn 2025 COVID-19 vaccination programme, but this is the deployment of remaining doses purchased as part of the original pandemic emergency response, not the result of a new supply agreement.
The COVID-19 vaccine market is transitioning from emergency pandemic procurement to routine immunization. Governments are now focusing on deploying existing stockpiles rather than placing large new orders, which means Comirnaty revenues are likely to decline compared to the peak pandemic years. BioNTech is actively diversifying its business through acquisitions and partnerships in oncology and other mRNA-based therapeutics, which may help offset declining COVID-19 vaccine income in the future.
Per the terms of its collaboration with Pfizer, BioNTech is entitled to half of the gross profits from sales of Comirnaty. The price per dose in the U.S. supply agreement is 27% higher than what was negotiated in prior agreements, suggesting a higher price for Comirnaty doses in the future. The effectiveness of BioNTech and Pfizer's omicron-specific booster against dominant viral variants could lead to increased demand for Comirnaty, potentially offsetting the decline in revenue due to the market normalization.
In summary, while there is no immediate boost to BioNTech’s net income from additional vaccine sales to governments or health systems due to the lack of new Comirnaty supply agreements, the new U.S. deal underscores the continued demand for the vaccine and could potentially lead to increased revenue in the future if the omicron-specific booster proves effective against dominant viral variants.
References: [1] BBC News, 2025. BioNTech and Pfizer secure new US deal for 105 million Covid jabs. [online] Available at:
- With the potential demand for up to 200 million more doses of Comirnaty, BioNTech's financial prospects in the health-and-wellness sector, specifically in the field of finance, could significantly improve.
- As BioNTech is entitled to half of the gross profits from Comirnaty sales, an increase in demand for the vaccine can have a direct impact on the company's finance, contributing to its revenue growth.
- The COVID-19 vaccine market is shifting, necessitating BioNTech to invest in oncology and other mRNA-based therapeutics to maintain its financial stability once the peak pandemic years have passed.
